Skip to content

Convidecia CanSino vaccine

Convidecia CanSino Vaccine is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics.

Convidecia-CanSino-vaccine

Production:  CanSinoBIO Biologics

Age requirements: 18 and above

Dosage: Single Dose.

European approval: March 22, 2021 (Hungary)

Storage: Safe, stable storage and transportation between 2°C and 8°C for three months, two months at 25°C, three weeks at 37°C

Effectiveness: 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination.

Pakistani authority showed an efficacy rate of 100% against severe COVID-19 disease and 74.8% in preventing all symptomatic COVID-19 disease. Convidecia-back

Advantages: Convidecia™ can be stably transported between 2°C and 8°C and stored for at least three months.

It is estimated to remain stable for over two months at 25°C and three weeks at 37°C. Making it more accessible to regions with insufficient storage facilities.

Wikipedia link: https://en.wikipedia.org/wiki/Convidecia

SOURCE: https://www.prnewswire.com/news-releases/cansinobio-announces-approval-for-its-single-dose-covid-19-vaccine-convidecia-in-hungary-301252978.html